top of page
.png)
Lyme Finance Dashboard
Financial analysis dashboard related to Lyme disease, outlining key economic and investment metrics. It highlights the annual economic burden of $1 billion, with a total annual cost of $3.1 billion, and an average treatment cost of $2,968 per patient. The dashboard includes a comparative analysis of Lyme disease economic costs and capital allocation, emphasizing trends in financial support and expenditures. Key funding details such as $524.5 million in federal and NIH contributions and $1,070 federal funding per new case are prominently displayed.
$1 Billion
Annual Economic Burden
$3.1 Billion
Total Annual Cost
$2,968
Chronic Lyme Disease Costs
87%
More Visits
Lyme Finance Overview
Summary:
-
Key Metrics: The Lyme Finance Dashboard highlights an 8.7% CAGR (2024-2030), $2,968 as the cost per chronic Lyme disease patient, and a significant economic impact led by the USA.
-
Economic Insights: The full economic impact of Lyme is highest in the USA, followed by Germany and Canada, reflecting substantial healthcare and indirect costs.
-
Funding Distribution: Federal and NIH funding in the USA dominate the financial landscape, with additional contributions from the UK government, emphasizing global support for Lyme disease initiatives.
.png)
Explore other Dashboards
bottom of page